Cerus to Present Cryoprecipitate Comparison Study in Liver Transplantation at 2026 AABB Meeting

By Public Technologies
  • Cerus will present transfusion research at the AABB Annual Meeting in Atlanta, Oct. 17-19, 2026.
  • Oral presentations will address platelet bacterial contamination on Oct. 17 and compare pathogen-reduced versus conventional cryoprecipitate in liver transplantation on Oct. 19.
  • An Oct. 18 workshop will examine Grady Health System's real-world experience implementing INTERCEPT Platelets and INTERCEPT Fibrinogen Complex.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014682249) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.